Paul W. Jones
- Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN studyBy Paul W. Jones, Dave Singh, Eric D. Bateman, Alvar Agusti, Rosa Lamarca, Gonzalo de Miquel, Rosa Segarra, Cynthia Caracta and Esther Garcia GilPaul W. Jones*St George's, University of London, LondonDave Singh#University of Manchester, Medicines Evaluation Unit Ltd, Manchester, UKEric D. Bateman¶University of Cape Town, Cape Town, South Africa,Alvar Agusti+Thorax Institute, Hospital Clínic, University of Barcelona, and Fundación Investigación Sanitaria Illes Balears (FISIB), Centro de Investigación Biomédica en Red Enfermedades Respiratorias (CIBERES), MallorcaRosa Lamarca§Almirall SA, Barcelona, SpainGonzalo de Miquel§Almirall SA, Barcelona, SpainRosa Segarra§Almirall SA, Barcelona, SpainCynthia CaractafForest Research Institute, Jersey City, NJ, USAEsther Garcia Gil§Almirall SA, Barcelona, Spain
- Multicentre European study for the treatment of advanced emphysema with bronchial valvesBy Vincent Ninane, Christian Geltner, Michela Bezzi, Pierfranco Foccoli, Jens Gottlieb, Tobias Welte, Luis Seijo, Javier J. Zulueta, Mohammed Munavvar, Antoni Rosell, Marta Lopez, Paul W. Jones, Harvey O. Coxson, Steven C. Springmeyer and Xavier GonzalezVincent NinaneChristian GeltnerMichela BezziPierfranco FoccoliJens GottliebTobias WelteLuis SeijoJavier J. ZuluetaMohammed MunavvarAntoni RosellMarta LopezPaul W. JonesHarvey O. CoxsonSteven C. Springmeyer
- A trial of beclomethasone/formoterol in COPD using EXACT-PRO to measure exacerbationsBy Dave Singh, Jorg Kampschulte, Jadwiga A. Wedzicha, Paul W. Jones, Géraldine Cohuet, Massimo Corradi, Tim Higenbottam, Stefano Petruzzelli and Jørgen VestboDave Singh*University of Manchester, Medicines Evaluation Unit, University Hospital of South Manchester Foundation Trust, Manchester Academic Health Science Centre, ManchesterJorg Kampschulte#Facharzt für Innere Medizin und Pneumologie, Berlin, GermanyJadwiga A. Wedzicha¶UCL Medical School, Academic Unit of Respiratory MedicinePaul W. Jones+St George's, University of London, Cardiac and Vascular Medicine, London, UKGéraldine Cohuet§Chiesi Corporate Clinical Development, Chiesi Farmaceutici SpA, ParmaMassimo CorradifDept of Clinical Medicine, Nephrology and Health Sciences, University of Parma, Parma, ItalyTim Higenbottam§Chiesi Corporate Clinical Development, Chiesi Farmaceutici SpA, ParmaStefano Petruzzelli§Chiesi Corporate Clinical Development, Chiesi Farmaceutici SpA, ParmaJørgen Vestbo*University of Manchester, Medicines Evaluation Unit, University Hospital of South Manchester Foundation Trust, Manchester Academic Health Science Centre, Manchester
- Comparisons of health status scores with MRC grades in COPD: implications for the GOLD 2011 classificationBy Paul W. Jones, Lukasz Adamek, Gilbert Nadeau and Norbert BanikPaul W. Jones1Division of Clinical Science, St George's University of London, LondonLukasz Adamek2Respiratory Centre of Excellence, GlaxoSmithKline, Uxbridge, UKGilbert Nadeau2Respiratory Centre of Excellence, GlaxoSmithKline, Uxbridge, UKNorbert Banik3Biostatistics and Epidemiology, GlaxoSmithKline, Munich, Germany
- Improvement in symptoms and rescue medication use with aclidinium bromide in patients with chronic obstructive pulmonary disease: Results from ATTAINBy Alvar Agusti, Paul W. Jones, Eric Bateman, David Singh, Rosa Lamarca, Gonzalo de Miquel, Cynthia Caracta and Esther Garcia GilAlvar Agusti1Thorax Institute, Hospital Clínic and CIBER Enfermedades Respiratorias and Fundaciό Caubet-Cimera, Barcelona, SpainPaul W. Jones2St George's, University of London, London, United KingdomEric Bateman3Department of Pulmonology, University of Cape Town, Cape Town, South AfricaDavid Singh4Medicines Evaluation Unit, University of South Manchester, Manchester, United KingdomRosa Lamarca5R&D Centre, Amirall, Barcelona, SpainGonzalo de Miquel5R&D Centre, Amirall, Barcelona, SpainCynthia Caracta6Clinical Development, Forest Research Institute, NJ, United StatesEsther Garcia Gil5R&D Centre, Amirall, Barcelona, Spain
- Determinants of health-related quality of life in patients with severe COPDBy Frits M.E. Franssen, Paul W. Jones, Martijn A. Spruit, Mariska Hartog and Emiel F.M. WoutersFrits M.E. Franssen1Program Development Center, Ciro, Horn, NetherlandsPaul W. Jones2St. George's, University of London, London, United KingdomMartijn A. Spruit1Program Development Center, Ciro, Horn, NetherlandsMariska Hartog1Program Development Center, Ciro, Horn, NetherlandsEmiel F.M. Wouters1Program Development Center, Ciro, Horn, Netherlands
- Can brain MRI explain cognitive decline in COPD? A pilot studyBy Rebecca A. Charlton, James W. Dodd, Martin van den Broek, Franklyn A. Howe, Thomas R. Barrick and Paul W. JonesRebecca A. Charlton1Clinical Sciences, St George's University of London, London, United KingdomJames W. Dodd1Clinical Sciences, St George's University of London, London, United KingdomMartin van den Broek2Department of Neurospychology, St George's NHS Trust, London, United KingdomFranklyn A. Howe1Clinical Sciences, St George's University of London, London, United KingdomThomas R. Barrick1Clinical Sciences, St George's University of London, London, United KingdomPaul W. Jones1Clinical Sciences, St George's University of London, London, United Kingdom
- The ATTAIN study: Safety and tolerability of aclidinium bromide in chronic obstructive pulmonary diseaseBy Eric D. Bateman, David Singh, Paul W. Jones, Alvar Agusti, Rosa Lamarca, Gonzalo de Miquel, Cynthia Caracta and Esther Garcia GilEric D. Bateman1Division of Pulmonology, Department of Medicine, University of Cape Town, Cape Town, South AfricaDavid Singh2Medicines Evaluation Unit, University of Manchester, Manchester, United KingdomPaul W. Jones3St George's, University of London, London, United KingdomAlvar Agusti4Thorax Institute, Hospital Clinic and CIBER Enfermedades Respiratorias and Fundaciό Caubet-Cimera, Barcelona, SpainRosa Lamarca5R&D Centre, Almirall, Barcelona, SpainGonzalo de Miquel5R&D Centre, Almirall, Barcelona, SpainCynthia Caracta6Clinical Development, Forest Research Institute, NJ, United StatesEsther Garcia Gil5R&D Centre, Almirall, Barcelona, Spain
- The ATTAIN study: Bronchodilatory effect of aclidinium bromide in chronic obstructive pulmonary disease (COPD)By David Singh, Eric D. Bateman, Paul W. Jones, Alvar Agusti, Rosa Lamarca, Gonzalo de Miquel, Cynthia Caracta and Esther Garcia GilDavid Singh1Medicines Evaluation Unit, University of Manchester, Manchester, United KingdomEric D. Bateman2Division of Pulmonology, University of Cape Town, Cape Town, South AfricaPaul W. Jones3St George's, University of London, London, United KingdomAlvar Agusti4Thorax Institute, Hospital Clínic and CIBER Enfermedades Respiratorias and Fundaciό Caubet-Cimera, Barcelona, SpainRosa Lamarca5R&D Centre, Almirall, Barcelona, SpainGonzalo de Miquel5R&D Centre, Almirall, Barcelona, SpainCynthia Caracta6Clinical Development, Forest Research Institute, NJ, United StatesEsther Garcia Gil5R&D Centre, Almirall, Barcelona, Spain
- Cognitive decline in stable and exacerbating COPD vs. controlsBy James W. Dodd, Rebecca A. Charlton, Martin van den Broek and Paul W. JonesJames W. Dodd1Clinical Sciences, St George's University of London, London, United KingdomRebecca A. Charlton1Clinical Sciences, St George's University of London, London, United KingdomMartin van den Broek2Department of Neuropsychology, St George's NHS Healthcare Trust, London, United KingdomPaul W. Jones1Clinical Sciences, St George's University of London, London, United Kingdom
- Aclidinium bromide in patients with chronic obstructive pulmonary disease: Improvement in health status in ATTAINBy Paul W. Jones, Alvar Agusti, Eric D. Bateman, David Singh, Rosa Lamarca, Gonzalo de Miquel, Cynthia Caracta and Esther Garcia GilPaul W. Jones1St George's, University of London, London, United KingdomAlvar Agusti2Thorax Institute, Hospital Clinic and CIBER Enfermedades Respiratorias and Fundaciό Caubet-Cimera, Barcelona, SpainEric D. Bateman3Department of Pulmonology, University of Cape Town, Cape Town, South AfricaDavid Singh4Medicines Evaluations Unit, University of Manchester, Manchester, United KingdomRosa Lamarca5R&D Centre, Almirall, Barcelona, SpainGonzalo de Miquel5R&D Centre, Almirall, Barcelona, SpainCynthia Caracta6Clinical Development, Forest Research Institute, NJ, United StatesEsther Garcia Gil5R&D Centre, Almirall, Barcelona, Spain
- Impact of symptoms of anxiety and depression on COPD Assessment Test scoresBy Christina W. Hilmarsen, Sarah Wilke, Harald Engan, Martijn A. Spruit, Johan Rodenburg, Daisy J.A. Janssen, Sigurd Steinshamn, Paul W. Jones, Emiel F.M. Wouters, Line Oldervoll and Frits M.E. FranssenChristina W. Hilmarsen1LHL Health Røros, Norwegian Heart and Lung Patient Organization, Røros9Both authors contributed equallySarah Wilke2Program Development Centre, CIRO+, Centre of Expertise for Chronic Organ Failure, Horn9Both authors contributed equallyHarald Engan1LHL Health Røros, Norwegian Heart and Lung Patient Organization, Røros3Dept of Engineering and Sustainable Development, Mid Sweden University, Östersund, SwedenMartijn A. Spruit2Program Development Centre, CIRO+, Centre of Expertise for Chronic Organ Failure, HornJohan Rodenburg1LHL Health Røros, Norwegian Heart and Lung Patient Organization, RørosDaisy J.A. Janssen2Program Development Centre, CIRO+, Centre of Expertise for Chronic Organ Failure, HornSigurd Steinshamn1LHL Health Røros, Norwegian Heart and Lung Patient Organization, Røros4Lung Dept, St Olav’s University Hospital, Trondheim5K.G. Jebsen Center of Exercise in Medicine, Dept of Circulation and Medical Imaging, Norwegian University of Technology and Science, TrondheimPaul W. Jones6Division of Clinical Science, St George’s University of London, London, UKEmiel F.M. Wouters2Program Development Centre, CIRO+, Centre of Expertise for Chronic Organ Failure, Horn7Dept of Respiratory Medicine, Maastricht University Medical Centre+ (MUMC+), Maastricht, The NetherlandsLine Oldervoll1LHL Health Røros, Norwegian Heart and Lung Patient Organization, Røros8Centre for Health Promotion, Institute for Social Work and Health Science, Norwegian University of Technology and Science, Trondheim, Norway10Both authors contributed equallyFrits M.E. Franssen2Program Development Centre, CIRO+, Centre of Expertise for Chronic Organ Failure, Horn10Both authors contributed equally
- Aclidinium bromide reduces COPD exacerbations as defined by healthcare utilisation and EXACT: Results from ATTAINBy Paul W. Jones, David Singh, Alvar Agusti, Eric D. Bateman, Rosa Lamarca, Gonzalo de Miquel, Cynthia Caracta and Esther Garcia GilPaul W. Jones1St George's, University of London, United KingdomDavid Singh2Medicines Evaluation Unit Ltd, Manchester, United KingdomAlvar Agusti3Thorax Institute, Hospital Clínic, Barcelona, and CIBER Enfermedades Respiratorias and Fundació Caubet-Cimera, Barcelona, SpainEric D. Bateman4University of Cape Town, South AfricaRosa Lamarca5Almirall S.A, Barcelona, SpainGonzalo de Miquel5Almirall S.A, Barcelona, SpainCynthia Caracta6Forest Research Institute, NJ, United StatesEsther Garcia Gil5Almirall S.A, Barcelona, Spain
- Efficacy and safety of twice-daily aclidinium bromide in COPD patients: The ATTAIN studyBy Paul W. Jones, Dave Singh, Eric D. Bateman, Alvar Agusti, Rosa Lamarca, Gonzalo de Miquel, Rosa Segarra, Cynthia Caracta and Esther Garcia GilArticle | Published in 2012 in European Respiratory JournalPaul W. JonesDave SinghEric D. BatemanAlvar AgustiRosa LamarcaGonzalo de MiquelRosa SegarraCynthia Caracta
- Impact of symptoms of anxiety and depression on COPD Assessment Test (CAT) scoresBy Christina Wikstrøm Hilmarsen, Sarah Wilke, Harald Engan, Martijn A. Spruit, Johan Rodenburg, Daisy J.A. Janssen, Sigurd Steinshamn, Paul W. Jones, Emiel F.M. Wouters, Line Oldervoll and Frits M.E. FranssenArticle | Published in 2013 in European Respiratory JournalChristina Wikstrøm Hilmarsen*LHL Health Röros, the Norwegian Heart and Lung Patient Organization, Norway¶¶Joint first authorSarah Wilke#Program Development Centre, CIRO+, Centre of Expertise for Chronic Organ Failure, Horn, the Netherlands¶¶Joint first authorHarald Engan*LHL Health Röros, the Norwegian Heart and Lung Patient Organization, Norway¶Dept of Engineering and Sustainable Development, Mid Sweden University, Östersund, SwedenMartijn A. Spruit#Program Development Centre, CIRO+, Centre of Expertise for Chronic Organ Failure, Horn, the NetherlandsJohan Rodenburg*LHL Health Röros, the Norwegian Heart and Lung Patient Organization, NorwayDaisy J.A. Janssen#Program Development Centre, CIRO+, Centre of Expertise for Chronic Organ Failure, Horn, the NetherlandsSigurd Steinshamn*LHL Health Röros, the Norwegian Heart and Lung Patient Organization, Norway+Lung Dept, St Olav's University Hospital, Trondheim, Norway§K.G. Jebsen Center of Exercise in Medicine, Dept of Circulation and Medical Imaging, Norwegian University of Technology and Science, Trondheim, NorwayPaul W. JonesfDivision of Clinical Science, St. George's University of London, London, United KingdomEmiel F.M. Wouters#Program Development Centre, CIRO+, Centre of Expertise for Chronic Organ Failure, Horn, the Netherlands**Dept of Respiratory Medicine, Maastricht University Medical Centre+, (MUMC+), Maastricht, the NetherlandsLine Oldervoll*LHL Health Röros, the Norwegian Heart and Lung Patient Organization, Norway##Centre for Health Promotion, Institute for Social Work and Health Science, Norwegian University of Technology and Science, Trondheim, Norway++Joint senior authorFrits M.E. Franssen#Program Development Centre, CIRO+, Centre of Expertise for Chronic Organ Failure, Horn, the Netherlands++Joint senior author
- Depression: a characteristic comorbidity of COPD?By Paul W. JonesPaul W. JonesInstitute for Infection and Immunity, St George’s, University of London, London, UK
- Paul W. JonesInstitute for Infection and Immunity, St George’s, University of London, London, UK
- Characterisation and impact of reported and unreported exacerbations: results from ATTAINBy Paul W. Jones, Rosa Lamarca, Ferran Chuecos, Dave Singh, Alvar Agustí, Eric D. Bateman, Gonzalo de Miquel, Cynthia Caracta and Esther Garcia GilArticle | Published in 2014 in European Respiratory JournalPaul W. Jones1Division of Clinical Science, St George’s, University of London, London, UKRosa Lamarca2R&D Centre, Almirall, Barcelona, SpainFerran Chuecos2R&D Centre, Almirall, Barcelona, SpainDave Singh3Medicines Evaluation Unit, University Hospital of South Manchester, Manchester, UKAlvar Agustí4Thorax Institute, Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain5FISIB, Centro de Investigación Biomédica en Red Enfermedades Respiratorias (CIBERES), Mallorca, SpainEric D. Bateman6Dept of Medicine, University of Cape Town, Cape Town, South AfricaGonzalo de Miquel2R&D Centre, Almirall, Barcelona, SpainCynthia Caracta7Forest Research Institute, Forest Laboratories Inc., Jersey City, NJ, USAEsther Garcia Gil2R&D Centre, Almirall, Barcelona, Spain
- Characterisation and impact of reported and unreported exacerbations: results from ATTAINBy Paul W. Jones, Rosa Lamarca, Ferran Chuecos, Dave Singh, Alvar Agustí, Eric D. Bateman, Gonzalo de Miquel, Cynthia Caracta and Esther Garcia GilPaul W. Jones1Division of Clinical Science, St George’s, University of London, London, UKRosa Lamarca2R&D Centre, Almirall, Barcelona, SpainFerran Chuecos2R&D Centre, Almirall, Barcelona, SpainDave Singh3Medicines Evaluation Unit, University Hospital of South Manchester, Manchester, UKAlvar Agustí4Thorax Institute, Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain5FISIB, Centro de Investigación Biomédica en Red Enfermedades Respiratorias (CIBERES), Mallorca, SpainEric D. Bateman6Dept of Medicine, University of Cape Town, Cape Town, South AfricaGonzalo de Miquel2R&D Centre, Almirall, Barcelona, SpainCynthia Caracta7Forest Research Institute, Forest Laboratories Inc., Jersey City, NJ, USAEsther Garcia Gil2R&D Centre, Almirall, Barcelona, Spain
- Inter-relationship of different types of respiratory symptoms in COPDBy Paul W. Jones, Marc Miravitlles, Ferran Chuecos, Esther Garcia Gil and Rosa LamarcaPaul W. Jones1Division of Clinical Science, St George’s, University of London, London, United KingdomMarc Miravitlles2Pneumology Department, Hospital Universitari Vall d’Hebron, Barcelona, SpainFerran Chuecos3R&D Centre, Almirall, Barcelona, SpainEsther Garcia Gil3R&D Centre, Almirall, Barcelona, SpainRosa Lamarca3R&D Centre, Almirall, Barcelona, Spain
- A prospective observational study of the impact of COPD on daily life following the initiation of indacaterolBy Paul W. Jones, Emma L. Low, Malcolm McCaughey, Abhijit Neil Banik, John Farley, Jason Victory, Jaymin B. Morjaria, Dinesh Saralaya, Su Mclain-Smith, Ruth M. Uden, Anzal Qurbain and Amr RadwanPaul W. Jones1Department of Respiratory Medicine, St George’s Healthcare NHS Trust, London, United KingdomEmma L. Low2Healthcare Consulting, Ph Associates, Marlow, Buckinghamshire, United KingdomMalcolm McCaughey3General Practice, Randalstown Medical Centre, Antrim, United KingdomAbhijit Neil Banik4General Practice, Park Farm Surgery, Folkestone, United KingdomJohn Farley5General Practice, Craigallian Avenue Medical Practice, Glasgow, United KingdomJason Victory6General Practice, Bradgate Surgery, Bristol, United KingdomJaymin B. Morjaria7Department of Respiratory Medicine, Hull and East Yorkshire NHS Hospital Trust, Hull, United KingdomDinesh Saralaya8Department of Respiratory Medicine, Bradford Teaching Hospitals NHS Foundation Trust, Bradford, United KingdomSu Mclain-Smith2Healthcare Consulting, Ph Associates, Marlow, Buckinghamshire, United KingdomRuth M. Uden2Healthcare Consulting, Ph Associates, Marlow, Buckinghamshire, United KingdomAnzal Qurbain9Primary Care Therapy, Novartis Pharmaceuticals Ltd, Camberley, United KingdomAmr Radwan9Primary Care Therapy, Novartis Pharmaceuticals Ltd, Camberley, United Kingdom
- Outcomes in Clinical TrialsEdited by Martin Kolb and Claus F. VogelmeierBook | Published in 2013DOI: 10.1183/1025448x.erm6213ISBN (electronic): 978-1-84984-045-3
- An official American Thoracic Society/European Respiratory Society statement: research questions in COPDBy Bartolome R. Celli, Marc Decramer, Jadwiga A. Wedzicha, Kevin C. Wilson, Alvar Agustí, Gerard J. Criner, William MacNee, Barry J. Make, Stephen I. Rennard, Robert A. Stockley, Claus Vogelmeier, Antonio Anzueto, David H. Au, Peter J. Barnes, Pierre-Regis Burgel, Peter M. Calverley, Ciro Casanova, Enrico M. Clini, Christopher B. Cooper, Harvey O. Coxson, Daniel J. Dusser, Leonardo M. Fabbri, Bonnie Fahy, Gary T. Ferguson, Andrew Fisher, Monica J. Fletcher, Maurice Hayot, John R. Hurst, Paul W. Jones, Donald A. Mahler, François Maltais, David M. Mannino, Fernando J. Martinez, Marc Miravitlles, Paula M. Meek, Alberto Papi, Klaus F. Rabe, Nicolas Roche, Frank C. Sciurba, Sanjay Sethi, Nikos Siafakas, Don D. Sin, Joan B. Soriano, James K. Stoller, Donald P. Tashkin, Thierry Troosters, Geert M. Verleden, Johny Verschakelen, Jorgen Vestbo, John W. Walsh, George R. Washko, Robert A. Wise, Emiel F.M. Wouters and Richard L. ZuWallackBartolome R. CelliFurther details of this ATS/ERS Task Force for COPD Research can be found in the acknowledgements section. 1Project co-chairs; should be considered co-first authorsMarc DecramerFurther details of this ATS/ERS Task Force for COPD Research can be found in the acknowledgements section. 1Project co-chairs; should be considered co-first authorsJadwiga A. WedzichaFurther details of this ATS/ERS Task Force for COPD Research can be found in the acknowledgements section. 1Project co-chairs; should be considered co-first authorsKevin C. WilsonFurther details of this ATS/ERS Task Force for COPD Research can be found in the acknowledgements section. 1Project co-chairs; should be considered co-first authorsAlvar AgustíFurther details of this ATS/ERS Task Force for COPD Research can be found in the acknowledgements section. 1Project co-chairs; should be considered co-first authorsGerard J. CrinerFurther details of this ATS/ERS Task Force for COPD Research can be found in the acknowledgements section. 1Project co-chairs; should be considered co-first authorsWilliam MacNeeFurther details of this ATS/ERS Task Force for COPD Research can be found in the acknowledgements section. 1Project co-chairs; should be considered co-first authorsBarry J. MakeFurther details of this ATS/ERS Task Force for COPD Research can be found in the acknowledgements section. 1Project co-chairs; should be considered co-first authorsStephen I. RennardFurther details of this ATS/ERS Task Force for COPD Research can be found in the acknowledgements section. 1Project co-chairs; should be considered co-first authorsRobert A. StockleyFurther details of this ATS/ERS Task Force for COPD Research can be found in the acknowledgements section. 1Project co-chairs; should be considered co-first authorsClaus VogelmeierFurther details of this ATS/ERS Task Force for COPD Research can be found in the acknowledgements section. 1Project co-chairs; should be considered co-first authorsAntonio AnzuetoFurther details of this ATS/ERS Task Force for COPD Research can be found in the acknowledgements section. 1Project co-chairs; should be considered co-first authorsDavid H. AuFurther details of this ATS/ERS Task Force for COPD Research can be found in the acknowledgements section. 1Project co-chairs; should be considered co-first authorsPeter J. BarnesFurther details of this ATS/ERS Task Force for COPD Research can be found in the acknowledgements section. 1Project co-chairs; should be considered co-first authorsPierre-Regis BurgelFurther details of this ATS/ERS Task Force for COPD Research can be found in the acknowledgements section. 1Project co-chairs; should be considered co-first authorsPeter M. CalverleyFurther details of this ATS/ERS Task Force for COPD Research can be found in the acknowledgements section. 1Project co-chairs; should be considered co-first authorsCiro CasanovaFurther details of this ATS/ERS Task Force for COPD Research can be found in the acknowledgements section. 1Project co-chairs; should be considered co-first authorsEnrico M. CliniFurther details of this ATS/ERS Task Force for COPD Research can be found in the acknowledgements section. 1Project co-chairs; should be considered co-first authorsChristopher B. CooperFurther details of this ATS/ERS Task Force for COPD Research can be found in the acknowledgements section. 1Project co-chairs; should be considered co-first authorsHarvey O. CoxsonFurther details of this ATS/ERS Task Force for COPD Research can be found in the acknowledgements section. 1Project co-chairs; should be considered co-first authorsDaniel J. DusserFurther details of this ATS/ERS Task Force for COPD Research can be found in the acknowledgements section. 1Project co-chairs; should be considered co-first authorsLeonardo M. FabbriFurther details of this ATS/ERS Task Force for COPD Research can be found in the acknowledgements section. 1Project co-chairs; should be considered co-first authorsBonnie FahyFurther details of this ATS/ERS Task Force for COPD Research can be found in the acknowledgements section. 1Project co-chairs; should be considered co-first authorsGary T. FergusonFurther details of this ATS/ERS Task Force for COPD Research can be found in the acknowledgements section. 1Project co-chairs; should be considered co-first authorsAndrew FisherFurther details of this ATS/ERS Task Force for COPD Research can be found in the acknowledgements section. 1Project co-chairs; should be considered co-first authorsMonica J. FletcherFurther details of this ATS/ERS Task Force for COPD Research can be found in the acknowledgements section. 1Project co-chairs; should be considered co-first authorsMaurice HayotFurther details of this ATS/ERS Task Force for COPD Research can be found in the acknowledgements section. 1Project co-chairs; should be considered co-first authorsJohn R. HurstFurther details of this ATS/ERS Task Force for COPD Research can be found in the acknowledgements section. 1Project co-chairs; should be considered co-first authorsPaul W. JonesFurther details of this ATS/ERS Task Force for COPD Research can be found in the acknowledgements section. 1Project co-chairs; should be considered co-first authorsDonald A. MahlerFurther details of this ATS/ERS Task Force for COPD Research can be found in the acknowledgements section. 1Project co-chairs; should be considered co-first authorsFrançois MaltaisFurther details of this ATS/ERS Task Force for COPD Research can be found in the acknowledgements section. 1Project co-chairs; should be considered co-first authorsDavid M. ManninoFurther details of this ATS/ERS Task Force for COPD Research can be found in the acknowledgements section. 1Project co-chairs; should be considered co-first authorsFernando J. MartinezFurther details of this ATS/ERS Task Force for COPD Research can be found in the acknowledgements section. 1Project co-chairs; should be considered co-first authorsMarc MiravitllesFurther details of this ATS/ERS Task Force for COPD Research can be found in the acknowledgements section. 1Project co-chairs; should be considered co-first authorsPaula M. MeekFurther details of this ATS/ERS Task Force for COPD Research can be found in the acknowledgements section. 1Project co-chairs; should be considered co-first authorsAlberto PapiFurther details of this ATS/ERS Task Force for COPD Research can be found in the acknowledgements section. 1Project co-chairs; should be considered co-first authorsKlaus F. RabeFurther details of this ATS/ERS Task Force for COPD Research can be found in the acknowledgements section. 1Project co-chairs; should be considered co-first authorsNicolas RocheFurther details of this ATS/ERS Task Force for COPD Research can be found in the acknowledgements section. 1Project co-chairs; should be considered co-first authorsFrank C. SciurbaFurther details of this ATS/ERS Task Force for COPD Research can be found in the acknowledgements section. 1Project co-chairs; should be considered co-first authorsSanjay SethiFurther details of this ATS/ERS Task Force for COPD Research can be found in the acknowledgements section. 1Project co-chairs; should be considered co-first authorsNikos SiafakasFurther details of this ATS/ERS Task Force for COPD Research can be found in the acknowledgements section. 1Project co-chairs; should be considered co-first authorsDon D. SinFurther details of this ATS/ERS Task Force for COPD Research can be found in the acknowledgements section. 1Project co-chairs; should be considered co-first authorsJoan B. SorianoFurther details of this ATS/ERS Task Force for COPD Research can be found in the acknowledgements section. 1Project co-chairs; should be considered co-first authorsJames K. StollerFurther details of this ATS/ERS Task Force for COPD Research can be found in the acknowledgements section. 1Project co-chairs; should be considered co-first authorsDonald P. TashkinFurther details of this ATS/ERS Task Force for COPD Research can be found in the acknowledgements section. 1Project co-chairs; should be considered co-first authorsThierry TroostersFurther details of this ATS/ERS Task Force for COPD Research can be found in the acknowledgements section. 1Project co-chairs; should be considered co-first authorsGeert M. VerledenFurther details of this ATS/ERS Task Force for COPD Research can be found in the acknowledgements section. 1Project co-chairs; should be considered co-first authorsJohny VerschakelenFurther details of this ATS/ERS Task Force for COPD Research can be found in the acknowledgements section. 1Project co-chairs; should be considered co-first authorsJorgen VestboFurther details of this ATS/ERS Task Force for COPD Research can be found in the acknowledgements section. 1Project co-chairs; should be considered co-first authorsJohn W. WalshFurther details of this ATS/ERS Task Force for COPD Research can be found in the acknowledgements section. 1Project co-chairs; should be considered co-first authorsGeorge R. WashkoFurther details of this ATS/ERS Task Force for COPD Research can be found in the acknowledgements section. 1Project co-chairs; should be considered co-first authorsRobert A. WiseFurther details of this ATS/ERS Task Force for COPD Research can be found in the acknowledgements section. 1Project co-chairs; should be considered co-first authorsEmiel F.M. WoutersFurther details of this ATS/ERS Task Force for COPD Research can be found in the acknowledgements section. 1Project co-chairs; should be considered co-first authorsRichard L. ZuWallackFurther details of this ATS/ERS Task Force for COPD Research can be found in the acknowledgements section. 1Project co-chairs; should be considered co-first authors
- An official American Thoracic Society/European Respiratory Society statement: research questions in COPDBy Bartolome R. Celli, Marc Decramer, Jadwiga A. Wedzicha, Kevin C. Wilson, Alvar A. Agustí, Gerard J. Criner, William MacNee, Barry J. Make, Stephen I. Rennard, Robert A. Stockley, Claus Vogelmeier, Antonio Anzueto, David H. Au, Peter J. Barnes, Pierre-Regis Burgel, Peter M. Calverley, Ciro Casanova, Enrico M. Clini, Christopher B. Cooper, Harvey O. Coxson, Daniel J. Dusser, Leonardo M. Fabbri, Bonnie Fahy, Gary T. Ferguson, Andrew Fisher, Monica J. Fletcher, Maurice Hayot, John R. Hurst, Paul W. Jones, Donald A. Mahler, François Maltais, David M. Mannino, Fernando J. Martinez, Marc Miravitlles, Paula M. Meek, Alberto Papi, Klaus F. Rabe, Nicolas Roche, Frank C. Sciurba, Sanjay Sethi, Nikos Siafakas, Don D. Sin, Joan B. Soriano, James K. Stoller, Donald P. Tashkin, Thierry Troosters, Geert M. Verleden, Johny Verschakelen, Jorgen Vestbo, John W. Walsh, George R. Washko, Robert A. Wise, Emiel F.M. Wouters and Richard L. ZuWallackBartolome R. CelliFurther details of this ATS/ERS Task Force for COPD Research can be found in the acknowledgements sectionMarc DecramerFurther details of this ATS/ERS Task Force for COPD Research can be found in the acknowledgements sectionJadwiga A. WedzichaFurther details of this ATS/ERS Task Force for COPD Research can be found in the acknowledgements sectionKevin C. WilsonFurther details of this ATS/ERS Task Force for COPD Research can be found in the acknowledgements sectionAlvar A. AgustíFurther details of this ATS/ERS Task Force for COPD Research can be found in the acknowledgements sectionGerard J. CrinerFurther details of this ATS/ERS Task Force for COPD Research can be found in the acknowledgements sectionWilliam MacNeeFurther details of this ATS/ERS Task Force for COPD Research can be found in the acknowledgements sectionBarry J. MakeFurther details of this ATS/ERS Task Force for COPD Research can be found in the acknowledgements sectionStephen I. RennardFurther details of this ATS/ERS Task Force for COPD Research can be found in the acknowledgements sectionRobert A. StockleyFurther details of this ATS/ERS Task Force for COPD Research can be found in the acknowledgements sectionClaus VogelmeierFurther details of this ATS/ERS Task Force for COPD Research can be found in the acknowledgements sectionAntonio AnzuetoFurther details of this ATS/ERS Task Force for COPD Research can be found in the acknowledgements sectionDavid H. AuFurther details of this ATS/ERS Task Force for COPD Research can be found in the acknowledgements sectionPeter J. BarnesFurther details of this ATS/ERS Task Force for COPD Research can be found in the acknowledgements sectionPierre-Regis BurgelFurther details of this ATS/ERS Task Force for COPD Research can be found in the acknowledgements sectionPeter M. CalverleyFurther details of this ATS/ERS Task Force for COPD Research can be found in the acknowledgements sectionCiro CasanovaFurther details of this ATS/ERS Task Force for COPD Research can be found in the acknowledgements sectionEnrico M. CliniFurther details of this ATS/ERS Task Force for COPD Research can be found in the acknowledgements sectionChristopher B. CooperFurther details of this ATS/ERS Task Force for COPD Research can be found in the acknowledgements sectionHarvey O. CoxsonFurther details of this ATS/ERS Task Force for COPD Research can be found in the acknowledgements sectionDaniel J. DusserFurther details of this ATS/ERS Task Force for COPD Research can be found in the acknowledgements sectionLeonardo M. FabbriFurther details of this ATS/ERS Task Force for COPD Research can be found in the acknowledgements sectionBonnie FahyFurther details of this ATS/ERS Task Force for COPD Research can be found in the acknowledgements sectionGary T. FergusonFurther details of this ATS/ERS Task Force for COPD Research can be found in the acknowledgements sectionAndrew FisherFurther details of this ATS/ERS Task Force for COPD Research can be found in the acknowledgements sectionMonica J. FletcherFurther details of this ATS/ERS Task Force for COPD Research can be found in the acknowledgements sectionMaurice HayotFurther details of this ATS/ERS Task Force for COPD Research can be found in the acknowledgements sectionJohn R. HurstFurther details of this ATS/ERS Task Force for COPD Research can be found in the acknowledgements sectionPaul W. JonesFurther details of this ATS/ERS Task Force for COPD Research can be found in the acknowledgements sectionDonald A. MahlerFurther details of this ATS/ERS Task Force for COPD Research can be found in the acknowledgements sectionFrançois MaltaisFurther details of this ATS/ERS Task Force for COPD Research can be found in the acknowledgements sectionDavid M. ManninoFurther details of this ATS/ERS Task Force for COPD Research can be found in the acknowledgements sectionFernando J. MartinezFurther details of this ATS/ERS Task Force for COPD Research can be found in the acknowledgements sectionMarc MiravitllesFurther details of this ATS/ERS Task Force for COPD Research can be found in the acknowledgements sectionPaula M. MeekFurther details of this ATS/ERS Task Force for COPD Research can be found in the acknowledgements sectionAlberto PapiFurther details of this ATS/ERS Task Force for COPD Research can be found in the acknowledgements sectionKlaus F. RabeFurther details of this ATS/ERS Task Force for COPD Research can be found in the acknowledgements sectionNicolas RocheFurther details of this ATS/ERS Task Force for COPD Research can be found in the acknowledgements sectionFrank C. SciurbaFurther details of this ATS/ERS Task Force for COPD Research can be found in the acknowledgements sectionSanjay SethiFurther details of this ATS/ERS Task Force for COPD Research can be found in the acknowledgements sectionNikos SiafakasFurther details of this ATS/ERS Task Force for COPD Research can be found in the acknowledgements sectionDon D. SinFurther details of this ATS/ERS Task Force for COPD Research can be found in the acknowledgements sectionJoan B. SorianoFurther details of this ATS/ERS Task Force for COPD Research can be found in the acknowledgements sectionJames K. StollerFurther details of this ATS/ERS Task Force for COPD Research can be found in the acknowledgements sectionDonald P. TashkinFurther details of this ATS/ERS Task Force for COPD Research can be found in the acknowledgements sectionThierry TroostersFurther details of this ATS/ERS Task Force for COPD Research can be found in the acknowledgements sectionGeert M. VerledenFurther details of this ATS/ERS Task Force for COPD Research can be found in the acknowledgements sectionJohny VerschakelenFurther details of this ATS/ERS Task Force for COPD Research can be found in the acknowledgements sectionJorgen VestboFurther details of this ATS/ERS Task Force for COPD Research can be found in the acknowledgements sectionJohn W. WalshFurther details of this ATS/ERS Task Force for COPD Research can be found in the acknowledgements sectionGeorge R. WashkoFurther details of this ATS/ERS Task Force for COPD Research can be found in the acknowledgements sectionRobert A. WiseFurther details of this ATS/ERS Task Force for COPD Research can be found in the acknowledgements sectionEmiel F.M. WoutersFurther details of this ATS/ERS Task Force for COPD Research can be found in the acknowledgements sectionRichard L. ZuWallackFurther details of this ATS/ERS Task Force for COPD Research can be found in the acknowledgements section
- Handling missing items in the Exacerbations of Chronic Pulmonary Disease ToolBy Andrew W. Hitchings, Emma H. Baker and Paul W. JonesArticle | Published in 2016 in European Respiratory JournalAndrew W. HitchingsInstitute for Infection and Immunity, St George's, University of London, London UKEmma H. BakerInstitute for Infection and Immunity, St George's, University of London, London UKPaul W. JonesInstitute for Infection and Immunity, St George's, University of London, London UK
Buying books on this site
Purchases made on this website are of electronic books only.
About the ERS books
The ERS Monograph is the quarterly book series from the European Respiratory Society. Each Monograph covers a specific area of respiratory medicine, providing in-depth reviews that give clinicians at all levels a concise, comprehensive guide to symptoms, diagnosis and treatment.
The ERS Handbooks are compact guides to broad areas of the respiratory field. Launched in 2010, the series now covers adult, paediatric and sleep respiratory medicine, includes a companion volume of self-assessment questions and features the ERS Practical Handbooks.